1. Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells. 2019, 8(5), 418, doi: 10.3390/cells8050418.
2. Kuwata T, Yanagihara K, Iino Y, Komatsu T, Ochiai A, Sekine S, Taniguchi H, Katai H, Kinoshita T, Ohtsu A. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts. Cells. 2019, 8(6), E585, doi: 10.3390/cells8060585.
3. Yanagihara K, Kubo T, Iino Y, Mihara K, Morimoto C, Seyama T, Kuwata T, Ochiai A, Yokozaki H. Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line. Oncotarget. 2019, 10(25), 2435-2450, doi: 10.18632/oncotarget.26764.
4. Ashizawa, T., A. Iizuka, C. Maeda, E. Tanaka, R. Kondou, H. Miyata, T. Sugino, T. Kawata, S. Deguchi, K. Mitsuya, N. Hayashi, A. Asai, M. Ito, K. Yamaguchi, Y. Akiyama. Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunol Lett. 2019, in press, doi: 10.1016/j.imlet.2019.10.003.
5. Ito R, Maruoka S, Gon Y, Katano I, Takahashi T, Ito M, Izuhara K, Nunomura S. Recent Advances in Allergy Research Using Humanized Mice. Int J Mol Sci, 2019, 20(11), E2740, doi: 10.3390/ijms20112740.
6. Ito R, Katano I, Otsuka I, Hanazawa A, Takahashi T, Kawai K, Yagoto M, Goto M, Ogura T, Takahashi R, Ito M. Exacerbation of pathogenic Th17-cell-mediated cutaneous graft-versus-host-disease in human IL-1beta and IL-23 transgenic humanized mice. Biochem Biophys Res Commun, 2019, 516(2), 480-485, doi: 10.1016/j.bbrc.2019.06.094.
7. 伊藤守.PDXモデルの特徴と免疫不全マウス,実験医学別冊「患者由来がんモデルを用いたがん研究実践ガイド」,2019年,144-148.
8. 伊藤守.NOGマウス概論,LABIO21,2019年,19-22.